Core revenue drivers grew 33% year over year for Castle Biosciences Inc. on August 5, 2025, with DecisionDx-Melanoma reports up 16% sequentially.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Core revenue drivers grew 33% year over year for Castle Biosciences Inc. on August 5, 2025, with DecisionDx-Melanoma reports up 16% sequentially.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Revenue Commissioners
customs, excise and taxation agency
Nothing else this week.
Coverage
Newest first; wire copies grouped- GuruFocus.comCastle Biosciences Inc (CSTL) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... Revenue: $86.2 million for Q2 2025, a decrease of 1% compared to Q2 2024. Test Report Volume: 26,574